696 related articles for article (PubMed ID: 27789359)
1. Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part II - Ocular drug-loaded lipid nanoparticles.
Sánchez-López E; Espina M; Doktorovova S; Souto EB; García ML
Eur J Pharm Biopharm; 2017 Jan; 110():58-69. PubMed ID: 27789359
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs.
Souto EB; Doktorovova S; Gonzalez-Mira E; Egea MA; Garcia ML
Curr Eye Res; 2010 Jul; 35(7):537-52. PubMed ID: 20597640
[TBL] [Abstract][Full Text] [Related]
3. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation.
Doktorovová S; Kovačević AB; Garcia ML; Souto EB
Eur J Pharm Biopharm; 2016 Nov; 108():235-252. PubMed ID: 27519829
[TBL] [Abstract][Full Text] [Related]
4. Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part I - Barriers and determining factors in ocular delivery.
Sánchez-López E; Espina M; Doktorovova S; Souto EB; García ML
Eur J Pharm Biopharm; 2017 Jan; 110():70-75. PubMed ID: 27789358
[TBL] [Abstract][Full Text] [Related]
5. Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals.
Puglia C; Bonina F
Expert Opin Drug Deliv; 2012 Apr; 9(4):429-41. PubMed ID: 22394125
[TBL] [Abstract][Full Text] [Related]
6. Lipid nanocarriers for dermal delivery of lutein: preparation, characterization, stability and performance.
Mitri K; Shegokar R; Gohla S; Anselmi C; Müller RH
Int J Pharm; 2011 Jul; 414(1-2):267-75. PubMed ID: 21596122
[TBL] [Abstract][Full Text] [Related]
7. Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits.
Chetoni P; Burgalassi S; Monti D; Tampucci S; Tullio V; Cuffini AM; Muntoni E; Spagnolo R; Zara GP; Cavalli R
Eur J Pharm Biopharm; 2016 Dec; 109():214-223. PubMed ID: 27789355
[TBL] [Abstract][Full Text] [Related]
8. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems.
Uner M
Pharmazie; 2006 May; 61(5):375-86. PubMed ID: 16724531
[TBL] [Abstract][Full Text] [Related]
9. Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles.
Leonardi A; Bucolo C; Romano GL; Platania CB; Drago F; Puglisi G; Pignatello R
Int J Pharm; 2014 Aug; 470(1-2):133-40. PubMed ID: 24792979
[TBL] [Abstract][Full Text] [Related]
10. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC.
Gonzalez-Mira E; Egea MA; Garcia ML; Souto EB
Colloids Surf B Biointerfaces; 2010 Dec; 81(2):412-21. PubMed ID: 20719479
[TBL] [Abstract][Full Text] [Related]
11. Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues.
Balguri SP; Adelli GR; Majumdar S
Eur J Pharm Biopharm; 2016 Dec; 109():224-235. PubMed ID: 27793755
[TBL] [Abstract][Full Text] [Related]
12. Lipid nanocapsules for dermal application: a comparative study of lipid-based versus polymer-based nanocarriers.
Abdel-Mottaleb MM; Neumann D; Lamprecht A
Eur J Pharm Biopharm; 2011 Sep; 79(1):36-42. PubMed ID: 21558002
[TBL] [Abstract][Full Text] [Related]
13. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir.
Seyfoddin A; Al-Kassas R
Drug Dev Ind Pharm; 2013 Apr; 39(4):508-19. PubMed ID: 22424312
[TBL] [Abstract][Full Text] [Related]
14. Application of Box-Behnken design for preparation of levofloxacin-loaded stearic acid solid lipid nanoparticles for ocular delivery: Optimization, in vitro release, ocular tolerance, and antibacterial activity.
Baig MS; Ahad A; Aslam M; Imam SS; Aqil M; Ali A
Int J Biol Macromol; 2016 Apr; 85():258-70. PubMed ID: 26740466
[TBL] [Abstract][Full Text] [Related]
15. Potential of Lipid Nanoparticles (SLNs and NLCs) in Enhancing Oral Bioavailability of Drugs with Poor Intestinal Permeability.
Talegaonkar S; Bhattacharyya A
AAPS PharmSciTech; 2019 Feb; 20(3):121. PubMed ID: 30805893
[TBL] [Abstract][Full Text] [Related]
16. Hansen solubility parameters (HSP) for prescreening formulation of solid lipid nanoparticles (SLN): in vitro testing of curcumin-loaded SLN in MCF-7 and BT-474 cell lines.
Doktorovova S; Souto EB; Silva AM
Pharm Dev Technol; 2018 Jan; 23(1):96-105. PubMed ID: 28949267
[TBL] [Abstract][Full Text] [Related]
17. Effect of drug solubility and lipid carrier on drug release from lipid nanoparticles for dermal delivery.
Zoubari G; Staufenbiel S; Volz P; Alexiev U; Bodmeier R
Eur J Pharm Biopharm; 2017 Jan; 110():39-46. PubMed ID: 27810471
[TBL] [Abstract][Full Text] [Related]
18. Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide.
Gonçalves LM; Maestrelli F; Di Cesare Mannelli L; Ghelardini C; Almeida AJ; Mura P
Eur J Pharm Biopharm; 2016 May; 102():41-50. PubMed ID: 26925503
[TBL] [Abstract][Full Text] [Related]
19. Stability of lipid excipients in solid lipid nanoparticles.
Radomska-Soukharev A
Adv Drug Deliv Rev; 2007 Jul; 59(6):411-8. PubMed ID: 17553589
[TBL] [Abstract][Full Text] [Related]
20. Solid lipid nanoparticles for ocular drug delivery.
Seyfoddin A; Shaw J; Al-Kassas R
Drug Deliv; 2010; 17(7):467-89. PubMed ID: 20491540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
